Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-269424
Filing Date
2025-11-06
Accepted
2025-11-06 16:00:49
Documents
50
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q crdf-20250930.htm   iXBRL 10-Q 2026089
2 EX-31.1 crdf-ex31_1.htm EX-31.1 14505
3 EX-31.2 crdf-ex31_2.htm EX-31.2 14386
4 EX-32.1 crdf-ex32_1.htm EX-32.1 7606
5 EX-32.2 crdf-ex32_2.htm EX-32.2 7487
  Complete submission text file 0001193125-25-269424.txt   7574230

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crdf-20250930.xsd EX-101.SCH 697307
52 EXTRACTED XBRL INSTANCE DOCUMENT crdf-20250930_htm.xml XML 1687524
Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35558 | Film No.: 251458023
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)